{"SPADE_UN_13488": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_13488", "Peptide Name": "Mastoparan-C [L1G, A5K]", "Source": "Synthetic construct", "Family": "Not found", "Gene": "N/A", "Sequence": "GNLKKLLAVAKKIL", "Sequence Length": 14, "UniProt Entry": ["http://www.uniprot.org/uniprot/P01516"], "Protein Existence": "Protein level", "Biological Activity": ["Antimicrobial", "Antibacterial", "Anti-Gram+", "Anti-Gram-"], "Target Organism": "[Ref.33285267]Gram-positive bacteria:Staphylococcus aureus ATCC 25923(MIC=16 µM); Bacillus subtilis ATCC 23857(MIC=4 µM);Gram-negative bacteria:Escherichia coli ATCC 25922(4.5 mM KCl and 0.004 mM FeCl3,MIC=4 µM); Pseudomonas aeruginosa ATCC 9027(0.004 mM FeCl3,MIC=4 µM); Klebsiella pneumoniae ATCC 700603(MIC=16 µM); Escherichia coli ATCC 25922(150mM NaCl,MIC=16 µM); Escherichia coli ATCC 25922(1mM MgCl2,MIC=8 µM); Pseudomonas aeruginosa ATCC 9027(NaCl/MgCl2=150mM/1mM,MIC=32 µM); Pseudomonas aeruginosa ATCC 9027(4.5mM KCl,MIC=16 µM); Escherichia coli(Rifampin-resistant strain,MIC=4 µM).", "Hemolytic Activity": "[Ref.33285267]0% hemolysis against mouse erythrocytes at 256 µM.", "Cytotoxicity": "[Ref.33285267]65% Killing against Human embryonic kidney HEK293T cells at 128 µM; Human embryonic kidney HEK293T cells(IC50=128 µM).", "Binding Target": "liposomes", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Amidation", "Stereochemistry": "L", "Structure Description": "The CD spectra in water adopts a random-coil conformation,22.26% α-helix was determined in50% TFE.", "Formula": "C71H133N19O16", "Mass": 1508.93, "PI": 10.48, "Net Charge": 4, "Hydrophobicity": 0.57, "Half Life": "Mammalian:30 hourYeast:>20 hourE.coli:>10 hour", "Function": "when combined with gentamicin, rifampin, and polymyxin B, it demonstrated synergistic or additive activity against E. coli ATCC 25922 and P. aeruginosa ATCC 9027.", "Literature": [{"Title": "Newly designed antimicrobial peptides with potent bioactivity and enhanced cell selectivity prevent and reverse rifampin resistance in Gram-negative bacteria.", "Pubmed ID": "33285267", "Reference": "Eur J Pharm Sci. 2021 Mar 1;158105665.", "Author": "Zhu N, Zhong C, Liu T, Zhu Y, Gou S, Bao H, Yao J, Ni J.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=33285267"}], "Frequent Amino Acids": "KLA", "Absent Amino Acids": "CDEFHMOPQRSTUWY", "Basic Residues": 4, "Acidic Residues": 0, "Hydrophobic Residues": 8, "Polar Residues": 8, "Positive Residues": 4, "Negative Residues": 0, "Similar Sequences": [{"SPADE_ID": "SPADE_UN_13478", "Similarity": 0.9285714285714286, "Sequence": "GNLKALLAVAKKIL"}, {"SPADE_ID": "SPADE_UN_13483", "Similarity": 0.9285714285714286, "Sequence": "LNLKKLLAVAKKIL"}, {"SPADE_ID": "SPADE_UN_13490", "Similarity": 0.9230769230769231, "Sequence": "LNLKKLLAVAKKI"}]}}}